Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial
A combination of Vaccitech’s experimental vaccine VTP-800 and Opdivo (nivolumab) appears to be a safe and potentially effective treatment for men with metastatic castration resistant prostate cancer (mCRPC), according to early data from a Phase 2a part of clinical trial. The open-label study (NCT03815942), called ADVANCE, may still be recruiting up to 36 patients in the U.K. It is sponsored and being conducted by the University of Oxford, and is co-funded by Vaccitech and the FP7 programme of the European Commission. The trial's main goal is to assess the safety and efficacy of VTP-800 when used in combination with Bristol-Myers Squibb's Opdivo at reducing blood levels of prostate-specific antigen (PSA) in men with intermediate risk or advanced prostate cancer. VTP-800 is a potential anti-cancer vaccine designed to prime the immune system to target and kill cancer cells. Specifically, it is intended to make the immune system kill cells with a protein called 5T4 on their surface. The vaccine is made of two engineered and harmless viruses, and designed to produce 5T4 in the body to help immune system to target this protein. Opdivo,  a type of t
Subscribe or to access all post and page content.